Under construction – not a live service
Sign in
Taking people in GreecePhase 1

Tests stem cell infusions and joint injections for rheumatoid arthritis

Tests donor stem cells from umbilical cord or placenta in people with rheumatoid arthritis.

Plain-language title generated from the registry record
Registry title: Safety of Cultured Allogeneic Adult Umbilical Cord or Placental Derived Mesenchymal Stem Cell Intravenous Infusion and Intra-Articular Injection for RA

Key facts

Where
Athens, GreeceSee the site
Phase
Phase 1

Where in Greece

  • Prodromos Stem Cell InstituteAthens, GreeceTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
The Foundation for Orthopaedics and Regenerative Medicine
Trial code
NCT05003934
Record updated
20 October 2026
Original description
This trial will study the safety and efficacy of intravenous infusion and intra-articular injection of cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cells for the treatment of Rheumatoid ArthritisRead full original descriptionShow less

Safety of Cultured Allogeneic Adult Umbilical Cord or Placental Derived Mesenchymal Stem Cell Intravenous Infusion and Intra-Articular Injection for the Treatment of Rheumatoid Arthritis

This trial will study the safety and efficacy of intravenous infusion and intra-articular injection of cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cells for the treatment of Rheumatoid Arthritis

Inclusion: Diagnosis of Rheumatoid Arthritis; Understanding and willingness to sign a written informed consent document.

Exclusion: Continued drug abuse; Previous organ transplant; Active infection; Active cancer; Chronic multisystem organ failure; Medical condition that would (based on the opinion of the investigator) compromise patient's safety; Hypersensitivity to sulfur; Clinically significant Abnormalities on pre-treatment laboratory evaluation; Pregnancy; Pre-menopausal women not using contraception.

ClinicalTrials.gov NCT05003934